Is Lynparib/Olaparib a targeted drug or a chemotherapy drug? Comprehensive analysis of the mechanism of action

Olaparib is a targeted drug that belongs to the PARP inhibitor class of drugs. It is mainly used to treat cancer patients with specific gene mutations, especially in the treatment of malignant tumors such as ovarian cancer, breast cancer, and prostate cancer. It has shown significant efficacy. Unlike traditional chemotherapy drugs, Lynparza does not work by directly killing cancer cells, but by specifically inhibiting the DNA repair mechanism of cancer cells, thereby rendering the cancer cells unable to repair their DNA damage, eventually leading to their death.

Olaparib works by inhibiting an enzyme called poly(ADP-ribose) polymerase (PARP), which plays an important role in the DNA repair process. Under normal circumstances, when a cell's DNA is damaged, PARP activates the repair mechanism to repair the damaged DNA. By inhibiting the activity of PARP enzyme, olaparib prevents the ability of cancer cells to repair DNA, especially cancer cells with BRCA gene mutations. The BRCA1 and BRCA2 genes are key genes responsible for repairing DNA double-strand breaks. When these genes are mutated, the repair mechanism of cancer cells becomes incomplete and relies on PARP for repair. Lynparza further aggravates DNA damage by inhibiting PARP, making these cancer cells unable to survive, ultimately leading to cancer cell death.

What is special about this mechanism of action is that olaparib can selectively act on cancer cells that already have DNA repair defects, while having relatively little impact on normal cells. Especially for patients with BRCA1 and BRCA2 mutations, the efficacy of olaparib is more significant. This is also where Lynparza differs from traditional chemotherapy drugs. Traditional chemotherapy drugs usually inhibit the growth of cancer cells by directly destroying the cell division mechanism. However, chemotherapy drugs are not only effective on cancer cells, but may also cause damage to normal cells, leading to serious side effects. The targeting effect of olaparib makes it relatively less likely to affect normal cells during treatment, thereby reducing common side effects of chemotherapy, such as nausea, hair loss, and immune system suppression.

Reference materials:https://www.lynparza.com/